Showing 3871-3880 of 8867 results for "".
- Study Links BMI and IBD Causally to Hidradenitis Suppurativahttps://practicaldermatology.com/news/mendelian-randomization-study-links-bmi-and-ibd-causally-to-hidradenitis-suppurativa/2485068/A new mendelian randomization (MR) analysis provides genetic evidence supporting a causal role for elevated body mass index (BMI) and inflammatory bowel disease (IBD) in hidradenitis suppurativa (HS). Study researchers used gen
- Contact Dermatitis, Unlabeled Ingredients Among Concerns in Self-Tannershttps://practicaldermatology.com/news/contact-dermatitis-unlabeled-ingredients-among-concerns-in-self-tanners/2485034/A recent review in the Journal of Drugs in Dermatology raised some concerns regarding ingredient safety and adverse reactions. Researchers on the study analyzed the top 50 best-selling sunless tanning products on Amazon
- Small Case Series Shows Promise for Topical Roflumilast in HS Treatmenthttps://practicaldermatology.com/news/topical-roflumilast-shows-early-promise-for-mild-hs-in-case-series/2485022/A prospective case series published in JAAD Case Reports suggests that once-daily topical roflumilast 0.3% cream may be a promising off-label treatment for mild hidradenitis suppurativa (HS).
- Most Insurers Cover Botulinum Toxin for Axillary Hyperhidrosis: Analysishttps://practicaldermatology.com/news/most-insurers-cover-botulinum-toxin-for-axillary-hyperhidrosis-analysis/2484933/A new cross-sectional study published in the Journal of Drugs in Dermatology finds that while botulinum toxin is broadly covered by private insurers for the treatment of primary axillary hyperhidrosis, access barriers due to
- Smoking, PROs, and Attrition May Skew HS Study Outcomes: Commentaryhttps://practicaldermatology.com/news/smoking-pros-and-attrition-may-skew-hs-study-outcomes/2484927/A letter to the editor published in JAAD provided commentary and presented additional opportunities for further research on adalimumab and the effects of smoking on patient response while treating hidradenitis suppurativa (HS).
- First Patient Enrolled in Nemolizumab Study for Chronic Itch Without Causehttps://practicaldermatology.com/news/first-patient-enrolled-in-nemolizumab-study-for-chronic-itch-without-cause/2484883/Galderma announced the enrollment first patient in a phase II clinical trial investigating nemolizumab for the treatment of Chronic Pruritus of Unknown Origin (CPUO), according to a press release from the manufacturer. The tr
- Survey Shows Common Skin Cancer Terms Often Misunderstoodhttps://practicaldermatology.com/news/common-skin-cancer-terms-often-misunderstood-survey-finds/2484880/A research letter looking at how well patients understand commonly used terminology related to skin published in JAMA Dermatology revealed significant gaps that could hinder informed decision-making, according to the study r
- Oral Roflumilast Suppresses Psoriatic Inflammation at the Gene and Cellular Level: Studyhttps://practicaldermatology.com/news/oral-roflumilast-suppresses-psoriatic-inflammation-at-the-gene-and-cellular-level/2484789/In a mechanistic substudy of the PSORRO trial, oral roflumilast demonstrated targeted immunomodulatory effects in patients with moderate-to-severe plaque psoriasis. Researchers for the vivo analysis sourght to characterize the dru
- MEL-SELF Analysis: Comparable Outcomes Between Affordable and Premium Dermatoscopeshttps://practicaldermatology.com/news/analysis-shows-comparable-outcomes-between-affordable-and-premium-dermatoscopes/2484733/A new randomized study embedded within the MEL-SELF trial suggests both low-cost and high-cost dermatoscopes enabled patients with a history of early-stage melanoma to effectively capture images for remote dermatologic assessment.
- Clascoterone 5% Solution Achieves Hair Regrowth in Large AGA Studyhttps://practicaldermatology.com/news/clascoterone-5-solution-acheives-hair-regrowth-in-large-aga-study/2484730/Cosmo Pharmaceuticals N.V. has reported phase 3 results from its two pivotal trials—Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805)—evaluating clascoterone 5% topical solution for male androgenetic alopecia (AGA). According t